LQDA
Liquidia Corporation
$34.35
-0.43
(-1.24%)
Mkt Cap
3.07B
Volume
4,237,458
52W Range
21.94-93.61
Sector
Healthcare
Beta
0.54
EPS (TTM)
1.57 USD
P/E Ratio
21.89
Revenue (TTM)
450.91M USD
Rev Growth (5Y)
+192.5%
EPS Growth (5Y)
N/A
Company Description
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158.32M | 14.00M | 17.49M | 15.94M | 12.85M | 739,628 | 8.07M | 2.71M | 7.26M | 13.22M |
| Net Income | (68.92M) | (130.39M) | (78.50M) | (41.02M) | (34.58M) | (59.76M) | (47.58M) | (53.14M) | (29.15M) | (15.93M) |
| EPS | -0.80 | -1.66 | -1.21 | -0.67 | -0.70 | -1.76 | -2.51 | -7.42 | -3.40 | -1.86 |
| Free Cash Flow | (40.02M) | (98.37M) | (42.85M) | (29.18M) | (34.14M) | (54.90M) | (50.13M) | (32.70M) | (26.83M) | (16.83M) |
| FCF / Share | -0.47 | -1.25 | -0.66 | -0.48 | -0.69 | -1.62 | -2.71 | -4.57 | -3.13 | -1.96 |
| Operating CF | (35.69M) | (93.42M) | (41.56M) | (28.59M) | (34.03M) | (54.14M) | (48.28M) | (31.83M) | (24.29M) | (13.95M) |
| Total Assets | 327.93M | 230.31M | 118.33M | 129.20M | 93.73M | 99.53M | 68.84M | 49.42M | 14.84M | 8.49M |
| Total Debt | 197.93M | 122.39M | 49.54M | 24.46M | 16.08M | 17.14M | 24.42M | 12.77M | 22.15M | 8.68M |
| Cash & Equiv | 190.68M | 176.48M | 83.68M | 93.28M | 57.49M | 65.32M | 55.80M | 39.53M | 3.42M | 1.44M |
| Book Value | 44.75M | 77.28M | 47.29M | 90.42M | 65.27M | 71.09M | 34.95M | 18.69M | (33.69M) | (18.25M) |
| Return on Equity | -1.54 | -1.69 | -1.66 | -0.45 | -0.53 | -0.84 | -1.36 | -2.84 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 171.68M | 132.87M | 92.02M | 54.34M | 8.84M | 3.12M | 2.92M | 4.45M | 3.66M | 2.97M | 4.53M | 3.68M |
| Net Income | 74.72M | 52.86M | 14.55M | (3.53M) | (41.58M) | (38.37M) | (38.37M) | (23.16M) | (27.94M) | (40.93M) | (27.45M) | (15.79M) |
| EPS | 0.84 | 0.60 | 0.17 | -0.04 | -0.49 | -0.45 | -0.45 | -0.30 | -0.37 | -0.54 | -0.42 | -0.24 |
| Free Cash Flow | 69.01M | (40.02M) | 42.21M | (10.68M) | (40.54M) | (31.01M) | (25.60M) | (26.83M) | (23.95M) | (25.49M) | (16.19M) | (22.04M) |
| FCF / Share | 0.78 | -0.45 | 0.48 | -0.12 | -0.47 | -0.36 | -0.30 | -0.34 | -0.31 | -0.34 | -0.25 | -0.34 |
| Operating CF | 80.24M | (35.69M) | 44.24M | (9.77M) | (39.48M) | (30.68M) | (20.81M) | (25.08M) | (22.66M) | (24.87M) | (15.98M) | (11.56M) |
| Total Assets | 521.92M | 401.53M | 327.93M | 275.98M | 257.41M | 227.43M | 230.31M | 252.89M | 177.36M | 197.12M | 118.33M | 111.64M |
| Total Debt | 128.94M | 184.82M | 197.93M | 199.18M | 200.38M | 147.66M | 122.39M | 2.69M | 2.95M | 3.23M | 49.54M | 3.77M |
| Cash & Equiv | 284.18M | 222.79M | 190.68M | 157.50M | 173.42M | 169.76M | 176.48M | 204.37M | 133.09M | 157.86M | 83.68M | 76.22M |
| Book Value | 195.11M | 108.58M | 44.75M | 22.05M | 15.19M | 49.71M | 77.28M | 110.52M | 62.72M | 86.26M | 47.29M | 48.01M |
| Return on Equity | 0.38 | 0.49 | 0.33 | -0.16 | -2.74 | -0.77 | -0.50 | -0.21 | -0.45 | -0.47 | -0.58 | -0.33 |
LQDA News
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
Liquidia (NASDAQ:LQDA) Shares Gap Up – Here’s Why
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA)